Blar i forfatter "Tekpli, Xavier"

Viser treff 1-2 av 2

    • Serglycin is Involved in TGF-β induced epithelial-mesenchymal transition and is highly expressed by immune cells in breast cancer tissue 

      Tellez Gabriel, Marta; Tekpli, Xavier; Reine, Trine M.; Hegge, Beate; Nielsen, Stephanie Rose; Chen, Meng; Moi, Line; Normann, Lisa Svartdal; Rasmussen Busund, Lill-Tove; Calin, George A.; Mælandsmo, Gunhild Mari; Perander, Maria; Theocharis, Achilleas D.; Kolset, Svein Olav; Knutsen, Erik (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-04-14)
      Serglycin is a proteoglycan highly expressed by immune cells, in which its functions are linked to storage, secretion, transport, and protection of chemokines, proteases, histamine, growth factors, and other bioactive molecules. In recent years, it has been demonstrated that serglycin is also expressed by several other cell types, such as endothelial cells, muscle cells, and multiple types of ...

    • Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers 

      Nome, Marianne Eikhom; Euceda, Leslie R.; Jabeen, Shakila; Debik, Julia; Bathen, Tone Frost; Giskeødegård, Guro F.; Tasken, Kristin Austlid; Mælandsmo, Gunhild Mari; Halvorsen, Bente; Yndestad, Arne; Borgen, Elin; Garred, Øystein; Aukrust, Pål; Ueland, Thor; Engebraaten, Olav; Kristensen, Vessela N.; Tekpli, Xavier (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-08-24)
      Angiogenesis is necessary for tumor growth and has been targeted in breast cancer; however, it is unclear which patients will respond and benefit from antiangiogenic therapy. We report noninvasive monitoring of patient response to neoadjuvant chemotherapy given alone or in combination with anti‐vascular endothelial growth factor (bevacizumab) in a randomized clinical trial. At four time points during ...